Evidence map›Paper›PMID 34021461›Full record

ArticleCardiovascular toxicology2021

Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism.

Yang Liu, Shuang Li, Zhanqun Gao, Shuangjia Li, Qingyun Tan, Yanmei Li, Dongwei Wang, Qingdong Wang

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Cardiovascular toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Footprint of Kynurenine Pathway in Cardiovascular Diseases.International journal of tryptophan research : IJTR · 2022
    Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yang Liu *Emergency Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Shuang Li *Emergency Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Zhanqun GaoEmergency Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Shuangjia LiEmergency Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Qingyun TanDepartment of Anesthesiology, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Yanmei LiEmergency Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Dongwei WangDepartment of Anesthesiology, First Affiliated Hospital of Jiamusi University, Jiamusi, China. mhnhua@163.com.
Qingdong WangDepartment of Anesthesiology, First Affiliated Hospital of Jiamusi University, Jiamusi, China. 3190013@qq.com.
First Affiliated Hospital of Jiamusi University · CN

Funding

The Health Commission of Heilongjiang Province 2019-314
6 · The paper itself

Abstract

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme for tryptophan metabolism, involved in immune cell differentiation/maturation and cancer biology. IDO1 is also expressed in cardiomyocytes, but its roles in the cardiovascular system are not fully understood. Here, we reported the functions of IDO1 during cardiac hypertrophy. Quantitative real-time PCR and Western blot experiments demonstrated the upregulation of IDO1 mRNA and protein levels in human and hypertrophic mouse hearts, as well as in angiotensin II (Ang II)-induced hypertrophic rat cardiomyocytes. IDO1 activity and metabolite product kynurenine were upregulated in rodent hypertrophic hearts and cardiomyocytes. Inhibition of IDO1 activity with PF-06840003 reduced Ang II-induced cardiac hypertrophy and rescued cardiac function in mice. siRNA-mediated knockdown of Ido1 repressed Ang II-induced growth in cardiomyocyte size and overexpression of hypertrophy-associated genes atrial natriuretic peptide (Anp or Nppa), brain natriuretic peptide (Bnp or Nppb), β-myosin heavy chain (β-Mhc or Myh7). By contrast, adenovirus-mediated rat Ido1 overexpression in cardiomyocytes promoted hypertrophic growth induced by Ang II. Mechanism analysis showed that IDO1 overexpression was associated with PI3K-AKT-mTOR signaling to activate the ribosomal protein S6 kinase 1 (S6K1), which promoted protein synthesis in Ang II-induced hypertrophy of rat cardiomyocytes. Finally, we provided evidence that inhibition of PI3K with pictilisib, AKT with perifosine, or mTOR with rapamycin, blocked the effects of IDO1 on protein synthesis and cardiomyocyte hypertrophy in Ang II-treated cells. Collectively, our findings identify that IDO1 promotes cardiomyocyte hypertrophy partially via PI3K-AKT-mTOR-S6K1 signaling.

Indexed as

AdultAgedAnimalsCardiomegalyCase-Control StudiesCells, CulturedDisease Models, AnimalFemaleHumansIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineMaleMiceMiddle AgedMyocytes, CardiacPhosphatidylinositol 3-KinaseIDO1 protein, humanIDO1 protein, mouseIdo1 protein, ratIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineMTOR protein, humanmTOR protein, mousemTOR protein, ratPhosphatidylinositol 3-KinaseProtein Kinase InhibitorsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesAKTCardiac hypertrophyIDO1MTORProtein synthesisS6K1

Identifiers

PMID34021461
PMCPMC8211584
OpenAlexW3162753642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.